0001016504 2025-07-01 2026-06-30 0001016504 2023-07-01 2024-06-30 0001016504 2024-07-01 2025-06-30 0001016504 2026-06-30 2025-07-01 2026-06-30 iso4217:USD false 0001016504 DEF 14A INTEGRATED BIOPHARMA, INC. true Clawback Policy The Company is not listed on either the New York Stock Exchange or the Nasdaq Stock Market and therefore isn’t required to and has not adopted a formal clawback policy with respect to the recovery of erroneously awarded compensation in the event of a financial restatement due to material noncompliance with any financial reporting requirement under the securities laws (with no fault required). Notwithstanding the absence of a formal policy, if the Board determines that an executive officer has engaged in fraudulent or intentional misconduct, the Board would take action to remedy the misconduct, prevent its recurrence, and impose such discipline on the wrongdoers as would be appropriate. Discipline would vary depending on the facts and circumstances, and may include, without limit, (1) termination of employment, (2) initiating an action for breach of fiduciary duty, and (3) if the misconduct resulted in a significant restatement of the Company’s financial results, seeking reimbursement of any portion of performance-based or incentive compensation paid or awarded to the executive that is greater than would have been paid or awarded if calculated based on the restated financial results. These remedies would be in addition to, and not in lieu of, any actions imposed by law enforcement agencies, regulators or other authorities. Equity Awards The Company’s equity incentive compensation program is designed to recognize scope of responsibilities, reward demonstrated performance and leadership, motivate future superior performance, align the interests of the executive with our stockholders’ and retain the executives through the term of the awards. We consider the grant size and the appropriate combination of stock options when making award decisions. The amount of equity incentive compensation grants are based upon the strategic, operational and financial performance of the Company overall and reflects the executives’ expected contributions to the Company’s future success. Existing ownership levels are not a factor in award determination, as we do not want to discourage executives from holding significant amounts of our stock. The timing of awards for the named executives is based on the annual awards for the named executives and any other employee awarded grants for the current year, which occurs at the first Board Meeting after the Compensation Committee meeting generally held in November, generally after the filing of the Company’s September Form 10-Q. The Compensation Committee does take into account the timing of the filing of the September Form 10-Q when determining the timing and terms of such an award and if the Compensation Committee meets prior to the filing of the September Form 10-Q, the measurement date of the award will be set to be 10 trading days after the filing of the September 10-Q. In all cases, the value of the award is calculated using the Volume Weighted Average Price over the past ten trading days and not at the end of anyone trading day. We have expensed stock option and RSU grants in accordance with United States generally accepted accounting principles. When determining the appropriate amount of stock options and RSUs, our goal is to weigh the cost of these grants with their potential benefits as a compensation tool. Stock options only have value to the extent the price of our stock on the date of exercise exceeds the exercise price on grant date, and thus are an effective compensation element only if the stock price grows over the term of the award. In this sense, stock options are a motivational tool. Each of the named executives received grants of stock options in the years ended June 30, 2026 and 2025. The stock options granted become exercisable in three (3) equal annual installments each on the annual anniversary date of the vesting date (December 9 and December 4, respectively) and have a maximum ten-year term (see outstanding equity table filed herein). We believe that this vesting schedule aids the Company in retaining executives and motivating longer-term performance. Under the terms of the Company’s equity incentive plan, unvested stock options and RSUs are forfeited if the executive voluntarily leaves the Company. There were no awards of RSU grants in the fiscal years ended June 30, 2026 and 2025. The Company’s equity incentive compensation program is designed to recognize scope of responsibilities, reward demonstrated performance and leadership, motivate future superior performance, align the interests of the executive with our stockholders’ and retain the executives through the term of the awards. We consider the grant size and the appropriate combination of stock options when making award decisions. The amount of equity incentive compensation grants are based upon the strategic, operational and financial performance of the Company overall and reflects the executives’ expected contributions to the Company’s future success. Existing ownership levels are not a factor in award determination, as we do not want to discourage executives from holding significant amounts of our stock. The timing of awards for the named executives is based on the annual awards for the named executives and any other employee awarded grants for the current year, which occurs at the first Board Meeting after the Compensation Committee meeting generally held in November, generally after the filing of the Company’s September Form 10-Q. The Compensation Committee does take into account the timing of the filing of the September Form 10-Q when determining the timing and terms of such an award and if the Compensation Committee meets prior to the filing of the September Form 10-Q, the measurement date of the award will be set to be 10 trading days after the filing of the September 10-Q. In all cases, the value of the award is calculated using the Volume Weighted Average Price over the past ten trading days and not at the end of anyone trading day. false false false Pay Versus Performance Table <div> <table cellpadding="0" cellspacing="0" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 75%; margin-left: 12.5%; margin-right: 12.5%;"> <tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Year(1) </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Summary Compensation Total For PEO($)(2) </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Compensation Actually Paid to PEO ($)(3) </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Average Summary Compensation for Non-PEO Named Executive Officers ($)(2) </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 13.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Average Compensation Actually Paid to Non-PEO Named Executive Officers ($)(3) </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Value of Initial Fixed $100 Investment Based on Total Shareholder Return ($)(4) </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 17.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Net Income (loss) ($)(in thousands)(5) </td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $350,732 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $349,208 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $360,744 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 13.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $364,100 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $34 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 17.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> $(2,842) </td> </tr> <tr style="background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 325,037 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 318,641 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 334,577 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 13.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 333,380 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 72 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 17.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 808 </td> </tr> <tr style="background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2024 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 331,301 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 315,189 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 343,719 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 13.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 328,805 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 42 </td> <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 17.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 112 </td> </tr> <tr> <td style="vertical-align: top; width: 10.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: top; width: 15.8%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: top; width: 13.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: top; width: 15.2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="vertical-align: top; width: 17.6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> </tbody></table> </div> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: "Times New Roman", Times, serif; width: 75%; margin-right: 12.5%; margin-left: 12.5%;"> <tbody><tr> <td style="width: 100%;">(1) For the Fiscal Year Ended June 30.</td> </tr> <tr> <td>(2) The Company’s Principal Executive Officer (“PEO”) are the Co-Chief Executive Officers, amount represents the amounts per the Summary Compensation Table Total for each of the Co-CEO’s and the Company’s only Non-PEO is its Chief Financial Officer and Senior Vice President.</td> </tr> <tr> <td>(3) Compensation Actually Paid was adjusted for changes in the estimated fair value of equity awards in accordance with Item (402(v) of Regulation S-K. Accordingly, the options awards disclosed in the Summary Compensation Table were deducted and the estimated fair value of any equity awards granted in the fiscal year were added and changes in fair value for vested and unvested awards from the previous fiscal year were either added or subtracted.</td> </tr> <tr> <td>(4) Calculated pursuant to Item 201(e) of Regulation S-K.</td> </tr> <tr> <td>(5) Net income (loss) for each of the fiscal year ended June 30.</td> </tr> </tbody></table> 350732 349208 360744 364100 34

-2842000

325037 318641 334577 333380 72

808000

331301 315189 343719 328805 42

112000